drugset / Trial / NCT00251082

Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

NCT00251082

Phase 3 Completed 391 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate efficacy of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone versus placebo in the treatment of vasomotor symptoms after a treatment period of 3 months and to investigate the bleeding pattern over a treatment period of one year

Timeline

Start
2005-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dydrogesterone Other / unclassified 2.5 mg
Comparator Dydrogesterone Other / unclassified 5 mg
Comparator Estradiol Other / unclassified 0.5 mg
Comparator Estradiol Other / unclassified 1 mg

Indications

No indication recorded.